Piper Jaffray today maintained an Overweight rating on MannKind (NASDAQ: MNKD) and boosted its price target to $8.40 (from $6.00). Analyst Ian Somaiya believes data will support FDA approval of Afrezza inhaled insulin. This will set the stage for a "lucrative licensing agreement" with potential partners that may include Bristol-Myers Squibb Company (NYSE: BMY) / AstraZeneca PLC (NYSE: AZN), Novo Nordisk (NYSE: NVO), Eli Lilly and Company (NYSE: LLY), or Sanofi (NYSE: SNY).
http://www.streetinsider.com/Analyst+Comments/MannKind+(MNKD)+Price+Target+Raised+to+$8.40+at+Piper/8450482.html
